title: How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
source: Yahoo
date: 2025-10-20
url: https://finnhub.io/api/news?id=6de96d6f076d49e026b5745298dbad36c6a6d1cacf760cb5423093e5aa1c1abc
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
